Zobrazeno 1 - 10
of 338
pro vyhledávání: '"M Scaltriti"'
Autor:
Mark E. Robson, Betty Ann Caravella, Mario E. Lacouture, Helen Won, Richard B. Lanman, M. Scaltriti, Neil Vasan, David B. Solit, Payal D. Shah, Aimee Cowan, Maura N. Dickler, Shanu Modi, Ronglai Shen, Elizabeth A. Comen, Weiyi Toy, Bob T. Li, Anne M. Covey, Komal Jhaveri, Sujata Patil, Jorge S. Reis-Filho, Rebecca J. Nagy, Pier Selenica, Pedram Razavi, Michael F. Berger, Stephen Zamora, Larry Norton, Mary Ellen Moynahan, Justin I. Odegaard, David N Brown, Clifford A. Hudis, Edi Brogi, Sarat Chandarlapaty, Andy Singh
Publikováno v:
Nature Cancer. 1:382-393
Alpelisib is a selective inhibitor of PI3Kα, shown to improve outcomes for PIK3CA mutant, hormone receptor positive (HR+) metastatic breast cancers (MBC) when combined with antiestrogen therapy. To uncover mechanisms of resistance, we conducted a de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::42df8bb7a3275c5f1e48f36c9fa0c54e
https://doi.org/10.1038/s43018-020-0047-1
https://doi.org/10.1038/s43018-020-0047-1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
A. Lluch, Antonio Llombart, Ana Vivancos, Patricia Villagrasa, Aleix Prat, Marcos Vinicius Silva Oliveira, Eva Ciruelos, I. Rapado, Joan Dorca, Laia Paré, Jordi Rodon, Marta Dueñas, Maria Vidal, Alvaro Montaño, Sonia Pernas, Fabiola Cecchi, Jordi Canes, Paolo Nuciforo, Antonia Perelló, Octavio Burgues, Gloria Ribas, M Scaltriti
Publikováno v:
Cancer Research. 79:P6-18
Background: Metastatic breast cancer is the second leading cause of death among women globally. A better understanding of tumor biology, and the availability of high-throughput technologies, have enabled the emergence of precision medicine bringing n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa5ce1a78e32b0f276fedbcbe99c8c18
https://doi.org/10.1158/1538-7445.sabcs18-p6-18-02
https://doi.org/10.1158/1538-7445.sabcs18-p6-18-02
Autor:
David M. Hyman, DJ Renouf, Anthony B. El-Khoueiry, Marcos Vinicius Silva Oliveira, J. Baselga, Kazuo Tamura, IA Mayer, J. Lindemann, Rhiannon Maudsley, Benoit You, Helen Ambrose, Udai Banerji, A Rutkowski, Gaia Schiavon, H Yamashita, TH Carr, A. Lluch, Alain C. Mita, E. De Bruin, Claire Corcoran, L.M. Smyth, Andrew Foxley, Martin Pass, S Chandarlapaty, Hideaki Bando, Eva Ciruelos, M Scaltriti, M.P. Sablin, Barry S. Taylor
Publikováno v:
Cancer Research. 78:P5-21
This abstract was withdrawn by the authors.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::166c98f0cce9aaedda8efa73d21f43ab
https://doi.org/10.1158/1538-7445.sabcs17-p5-21-05
https://doi.org/10.1158/1538-7445.sabcs17-p5-21-05
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Frauke Schimmoller, Jose Baselga, Abiha Kazmi, Barry S. Taylor, Sarat Chandarlapaty, Lewis C. Cantley, Lori S. Friedman, Eneda Toska, Hardik Shah, Jared L. Johnson, Robert Sebra, Pedram Razavi, Ed Reznik, Raul Rabadan, Hong Shao, Alexander Gorelick, Guotai Xu, Alesia Antoine, Matthew T. Chang, Komal Jhaveri, Neil Vasan, Ting-Yu Lin, M Scaltriti, Erik Ladewig, Melissa Smith, T. R. Wilson, Maura N. Dickler
Publikováno v:
Cancer Research. 80:NG16-NG16
PIK3CA is the most frequently mutated oncogene across all human cancers, and codes for p110α, the catalytic subunit of the PI3K complex. PI3K catalyzes the phosphorylation of the lipid PIP2 to PIP3, which initiates a downstream signaling cascade inv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb145423894c024bbc12ed88ef6f685b
https://doi.org/10.1158/1538-7445.am2020-ng16
https://doi.org/10.1158/1538-7445.am2020-ng16
Autor:
O. Abdel-Wahab, A. Akcakanat, S.E. Boyle, T. Brabb, C. Brayton, A. Bruna, D.M. Burgenske, J.W. Cassidy, S. Chateau-Joubert, W. Cheng, Y. Chen, L.A. Colby, E. Corwin, E. de Stanchina, O. Duchamp, J. Eswaraka, K.W. Evans, B. Fang, C.G. Fedele, J.B. Fleming, J.-J. Fontaine, A. Giddabasappa, E. Girard, L.R. Hill, D.K. Hirenallur-Shanthappa, G.Y. Ho, G. Inghirami, B.M. Iritani, Y. Jiang, S.D. Kaffenberger, A. Krivtsov, M.G. Lawrence, L. Liang, J. Liu, J.P. MacKeigan, E. Marangoni, M. Mattar, I. Mercado-Uribe, F. Meric-Bernstam, G.B. Mills, N. Niu, J.M. Olson, N. Paez-Arango, K. Paz, K. Pham, S.P.S. Pillai, M. Pizzi, J.T. Poirier, J.A. Ramírez, M.V. Rios Perez, G. Risbridger, P.J. Russell, P. Sathyan, M. Scaltriti, S.C. Schmechel, C. Scott, C.L. Scott, J.-L. Servely, M. Shackleton, B.W. Simons, J. Snyder, A.K. Sood, A.D. Strand, R. Taylor, S. Thompson-Iritani, P.T. Tinkey, R. Uthamanthil, L. Wang, E.D. Williams, E. Yuca, J. Zhang, R. Zhang
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e3077c26722574fdf1ca460ec5178d45
https://doi.org/10.1016/b978-0-12-804010-2.01002-x
https://doi.org/10.1016/b978-0-12-804010-2.01002-x
Autor:
M Scaltriti, Massimo Aglietta, Jeff Sperinde, Aleix Prat, Giorgio Valabrega, Michela Donadio, Filippo Montemurro, Patricia Galván, Valentina A. Rossi, Anna Sapino, C Peraldo-Neia, J. Baselga
Publikováno v:
Cancer Research. 73:P1-08
Purpose: In 2009 we started a prospective, randomized Phase II trial to evaluate HER2-targeting without chemotherapy (CT) in HER2-positive (HER2+) metastatic breast cancer (MBC) patients (pts). Although the study was prematurely closed because of slo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0dddb4cf275dd1641a6b0c2600117efb
https://doi.org/10.1158/0008-5472.sabcs13-p1-08-23
https://doi.org/10.1158/0008-5472.sabcs13-p1-08-23
Autor:
H Eidtmann, Ludmila Prudkin, M Scaltriti, J. Baselga, Jeff Sperinde, Catherine E. Ellis, Nadia Harbeck, M.J. Piccart, Josep Lluis Parra, Violeta Serra, Ian Bradbury, Paolo Nuciforo, Joaquín Arribas, Lajos Pusztai
Publikováno v:
Cancer Research. 73:P1-08
Background: Expression of p95HER2, a truncated form of HER2 lacking the extracellular domain, has been associated with resistance to trastuzumab (T)-based therapy in metastatic breast cancer patients. Conversely, high levels of HER2 have been correla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::772b93cbf013690724a61582b52cd3c3
https://doi.org/10.1158/0008-5472.sabcs13-p1-08-42
https://doi.org/10.1158/0008-5472.sabcs13-p1-08-42
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.